Photodynamic therapy as a promising approach for urinary tract tumors: Current evidence and future challenges
Abstract
Photodynamic therapy (PDT) is an advanced treatment method extensively used in oncology and other medical fields due to its ability to selectively destroy pathological cells. PDT operates through the activation of photosensitizers (PS) by light of a specific wavelength, resulting in the formation of reactive oxygen species (ROS) that cause cellular damage. PDT can be classified into three main approaches: tumor-targeted PDT, vascular-targeted PDT, and antimicrobial PDT. In oncology, PDT is predominantly used to target cancer cells while minimizing damage to healthy tissues. Additionally, PDT has shown promise in the diagnosis and treatment of bladder tumors, expanding its role in urological oncology. The mechanism of PDT in prostate cancer highlights its ability to target tumor vasculature, inducing ischemic necrosis while preserving surrounding tissues. The evolution of photosensitizers, particularly in prostate cancer, has led to second-generation compounds that offer faster, more efficient treatments with fewer side effects.
Get full access to this article
View all access and purchase options for this article.
References
1. Alvarez N, Sevilla A. Current advances in photodynamic therapy (PDT) and the future potential of PDT-combinatorial cancer therapies. Int. J. Mol. Sci 2024; 25: 1023.
2. Shirasu N, Nam SO, Kuroki M. Tumor-targeted photodynamic therapy. Anticancer Res 2013; 33: 2823–2831.
3. Nogueira L, Tracey AT, Alvim R, et al. Developments in vascular-targeted photodynamic therapy for urologic malignancies. Molecules 2020; 25: 5417.
4. Jao Y, Ding SJ, Chen CC. Antimicrobial photodynamic therapy for the treatment of oral infections: a systematic review. J Dent Sci 2023; 18: 1453–1466.
5. Flegar L, Buerk B, Proschmann R, et al. Vascular-targeted photodynamic therapy in unilateral low-risk prostate cancer in Germany: 2-yr single-centre experience in a real-world setting compared with radical prostatectomy. Eur Urol Focus 2022; 8: 121–127.
6. Aebisher D, Serafin I, Batóg-Szczęch K, et al. Photodynamic therapy in the treatment of cancer-the selection of synthetic photosensitizers. Pharmaceuticals (Basel 2024; 17: 32.
7. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J 2016; 473: 347–364.
8. Korotkova I, Sakhno T. Nanoparticles with the aggregation-induced emission effect: properties and applications: photosensitizers for photodynamic therapy. Saarbrücken: LAP LAMBERT Academic Publishing, 2020, pp.1–93.
9. Olszowy M, Nowak-Perlak M, Woźniak M. Current strategies in photodynamic therapy (PDT) and photodynamic diagnostics (PDD) and the future potential of nanotechnology in cancer treatment. Pharmaceutics 2023; 15: 1712.
10. Minaev BF, Yashchuk LB. Possible electronic mechanisms of generation and quenching of luminescence of singlet oxygen in the course of photodynamic therapy: ab initio study. Biopolym. Cell 2006; 22: 231–235.
11. Minaev B. Magnetic properties of reactive oxygen Species and their possible role in cancer therapy. Arch Cancer Sci Ther 2024; 8: 048–053.
12. Bregnhøj M, Westberg M, Minaev BF, et al. Singlet oxygen photophysics in liquid solvents: converging on a unified picture. Acc Chem Res 2017; 50: 1920–1927.
13. Loboda O, Tunell I, Minaev B, et al. Theoretical study of triplet state properties of free-base porphin. Chem Phys 2005; 312: 299–309.
14. Minaev BF. Quantum-chemical investigation of the mechanisms of the photosensitization, luminescence, and quenching of singlet1Δg oxygen in solutions. J. of Appl. Spectroscopy 1985; 42: 518–523.
15. Valiev RR, Nasibullin RT, Cherepanov VN, et al. First-principles calculations of anharmonic and deuteration effects on the photophysical properties of polyacenes and porphyrinoids. Phys. Chem. Chem. Phys 2020; 22: 22314–22323.
16. Aebisher D, Czech S, Dynarowicz K, et al. Photodynamic therapy: past, current, and future. Int J Mol Sci 2024; 25: 11325.
17. Dagar G, Gupta A, Shankar A, et al. The future of cancer treatment: combining radiotherapy with immunotherapy. Front Mol Biosci 2024; 11: 1409300.
18. Zhang P, Han T, Xia H, et al. Advances in photodynamic therapy based on nanotechnology and its application in skin cancer. Front Oncol 2022; 12: 836397.
19. Sakhno T, Sakhno Y, Kuchmiy S. Clusteroluminescence in organic, inorganic, and hybrid systems: a review. Theor. Exp. Chem 2022; 58: 297–327.
20. Sakhno T, Sakhno Y, Kuchmiy S. Clusteroluminescence of unconjugated polymers: a review. Theor. Exp. Chem 2023; 59: 75–106.
21. Wang X, Ding X, Yu B, et al. Tumor microenvironment-responsive polymer with chlorin e6 to interface hollow mesoporous silica nanoparticles-loaded oxygen supply factor for boosted photodynamic therapy. Nanotechnology 2020; 31: 305709.
22. Sakhno T, Ivashchenko D, Semenov A, et al. Clusteroluminogenic polymers: applications in biology and medicine (review article). Low Temp Phys 2024; 50: 276–287.
23. Hong G, Chang JE. Enhancing cancer treatment through combined approaches: photodynamic therapy in concert with other modalities. Pharmaceutics 2024; 16: 1420.
24. Aebisher D, Szpara J, Bartusik-Aebisher D. Advances in medicine: photodynamic therapy. Int J Mol Sci 2024; 25: 8258.
25. Grynyov B, Sakhno T, Senchishin V. Optically transparent and fluorescent polymers. Kharkiv, 2003, p. 1-575.
26. Valiev R, He Y, Weltzin T, et al. Wavelength-dependent intersystem crossing dynamics of phenolic carbonyls in wildfire emissions. Phys. Chem. Chem. Phys 2025; 27: 998–1007.
27. Korneev O, Sakhno T, Korotkova I. Nanoparticles-based photosensitizers with effect of aggregation-induced emission. Biopolymers and Cell 2019; 35: 249–267.
28. Barashkov N, Sakhno T, Nurmukhametov R, et al. Excimers of organic molecules. Russian Chem. Reviews 1993; 62: 539–552.
29. Dias LD, Mfouo-Tynga IS. Learning from nature: bioinspired chlorin-based photosensitizers immobilized on carbon materials for combined photodynamic and photothermal therapy. Biomimetics (Basel) 2020; 5: 53.
30. Lima E, Reis LV. Photodynamic therapy: from the basics to the current progress of N-heterocyclic-bearing dyes as effective photosensitizers. Molecules 2023; 28: 5092.
31. Plotnikov V. Regularities of the processes of radiationless conversion in polyatomic molecules. Intern. J. of Quantum Chem 1979; 16: 527–541.
32. Ni J, Wang Y, Zhang H, et al. Aggregation-Induced generation of reactive oxygen Species: mechanism and photosensitizer construction. Molecules 2021; 26: 68.
33. Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother 2018; 106: 1098–1107.
34. Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clin Endosc 2013; 46: 24–29.
35. Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 2009; 96: –8.
36. Mushtaq A, Zhang H, Cui M, et al. Corrigendum to “ROS-responsive chlorin e6 and silk fibroin loaded ultrathin magnetic hydroxyapatite nanorods for T1-magnetic resonance imaging guided photodynamic therapy in vitro” colloids surf. A: physicochem. Eng. Aspects 656 (part B). Colloids Surf, A 2023; 665: 130513.
37. Kumar R, Dalal D, Gupta K, et al. Photodynamic therapy and ROS. In: Chakraborti S (ed.) Handbook of oxidative stress in cancer: therapeutic aspects. Singapore: Springer, 2022, pp.1325–1335.
38. Dąbrowski J. Chapter nine - reactive oxygen Species in photodynamic therapy: mechanisms of their generation and potentiation. Adv Inorg Chem 2017; 70: 343–394.
39. Minaev B. Spin-orbit coupling mechanism of singlet oxygen a1Δg quenching by solvent vibrations. Chem Phys 2017; 483: 84–95.
40. Fonseca SM, Pina J, Arnaut LG, et al. Triplet-state and singlet oxygen formation in fluorene-based alternating copolymers. J Phys Chem B 2006; 110: 8278–8283.
41. Erden I, Karadoğan B, Kılıçarslan FA, et al. New soluble 4-(4-formyl-2,6-dimethoxyphenoxy) substituted phthalocyanines: synthesis, characterization, photophysical and photochemical properties. Main Group Chem 2022; 21: 421–430.
42. Correia JH, Rodrigues JA, Pimenta S, et al. Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharmaceutics 2021; 13: 1332.
43. Kessel D, Oleinick NL. Photodynamic therapy and cell death pathways. Methods Mol Biol 2010; 635: 35–46.
44. Donohoe C, Senge MO, Arnaut LG, et al. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer 2019; 1872: 188308.
45. Kutlu ÖD, Avcil D, Erdoğmuş A. New water-soluble cationic indium (III) phthalocyanine bearing thioquinoline moiety; synthesis, photophysical and photochemical studies with high singlet oxygen yield. Main Group Chem 2019; 18: 139–151.
46. Öncül GA, Öztürk ÖF, Pişkin M. Spectroscopic and photophysicochemical properties of zinc(II) phthalocyanine substituted with benzenesulfonamide units containing schiff base. Main Group Chem 2022; 21: 997–1011.
47. Marcus S, McIntyre W. Photodynamic therapy systems and applications. Expert Opin Emerg Drugs 2002; 7: 321–334.
48. Fukuhara H, Yamamoto S, Karashima T, et al. Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy. Int J Clin Oncol 2021; 26: 18–25.
49. Taoka R, Matsuoka Y, Yamasaki M, et al. Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. Photodiagnosis Photodyn Ther 2022; 38: 102838.
50. Werner M, Lyu C, Stadlbauer B, et al. The role of shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. Photodiagnosis Photodyn Ther 2022; 39: 102987.
51. Avendaño C, Menéndez J. Anticancer strategies involving radical species medicinal chemistry of anticancer drugs (third edition). Elsevier, 2023; 165–235.
52. Azzouzi AR, Lebdai S, Benzaghou F, et al. Vascular-targeted photodynamic therapy with TOOKAD® soluble in localized prostate cancer: standardization of the procedure. World J Urol 2015; 33: 937–944.
53. Kubrak T, Karakuła M, Czop M, et al. Advances in management of bladder cancer-the role of photodynamic therapy. Molecules 2022; 27: 31.
54. Azzouzi A, Barret E, Moore C, et al. TOOKAD((R)) soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 2013; 112: 766–774.
55. Lorenz KJ, Maier H. Squamous cell carcinoma of the head and neck. Photodynamic therapy with foscan] [article in German. HNO 2008; 56: 402–409.
56. Kikuchi T, Asakura T, Aihara H, et al. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study. Anticancer Res 2003; 23: 4897–4900.
57. Fan L, Jiang Z, Xiong Y, et al. Recent advances in the HPPH-based third-generation photodynamic agents in biomedical applications. Int J Mol Sci 2023; 24: 17404.
58. Hunt DW. Rostaporfin (miravant medical technologies). IDrugs 2002; 5: 180–186.
59. Mang TS, Allison R, Hewson G, et al. A phase II/III clinical study of tin ethyl etiopurpurin (purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am 1998; 4: 378–384.
60. Wong JJW, Lorenz S, Selbo PK. All-trans retinoic acid enhances the anti-tumour effects of fimaporfin-based photodynamic therapy. Biomed Pharmacother 2022; 155: 113678.
61. Moore CM, Emberton M, Bown SG. Photodynamic therapy for prostate cancer–an emerging approach for organ-confined disease. Lasers Surg Med 2011; 43: 768–775.
62. Hsi RA, Kapatkin A, Strandberg J, et al. Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res 2001; 7: 651–660.
63. Du KL, Mick R, Busch TM, et al. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med 2006; 38: 427–434.
64. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976; 115: 150–151.
65. Datta SN, Loh CS, MacRobert AJ, et al. Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma. Br J Cancer 1998; 78: 1113–1118.
66. van den Boogert J, van Hillegersberg R, de Rooij FW, et al. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B 1998; 44: 29–38.
67. Zaak D, Frimberger D, Stepp H, et al. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 2001; 166: 1665–1669.
68. Unyime O. Photodynamic therapy. Urol Clin N Am 1992; 19: 591–599.
69. Fabre MA, Fuseau E, Ficheux H. Selection of dosing regimen with WST11 by monte carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling. J Pharm Sci 2007; 96: 3444–3456.
70. Gross S, Gilead A, Scherz A, et al. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003; 9: 1327–1331.
71. Madar-Balakirski N, Tempel-Brami C, Kalchenko V, et al. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with tookad. PLoS One 2010; 5: e10282.
72. Noweski A, Roosen A, Lebdai S, et al. Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD soluble WST-11 (phase II trials). Eur Urol Focus 2019; 5: 1022–1028.
73. Gheewala T, Skwor T, Munirathinam G. Photosensitizers in prostate cancer therapy. Oncotarget 2017; 8: 30524–30538.
74. Chen Q, Huang Z, Luck D, et al. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol 2002; 76: 438–445.
75. Huang Z, Chen Q, Dole KC, et al. The effect of tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues—in vivo study in a canine model. Photochem Photobiol Sci 2007; 6: 1318–1324.
76. Huang Z, Chen Q, Trncic N, et al. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation. Radiat Res 2004; 161: 723–731.
77. Dole KC, Chen Q, Hetzel FW, et al. Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model. Photomed Laser Surg 2005; 23: 172–176.
78. Pinho S, Coelho JMP, Gaspar MM, et al. Advances in localized prostate cancer: a special focus on photothermal therapy. Eur J Pharmacol 2024; 983: 176982.
79. Tracey AT, Nogueira LM, Alvim RG, et al. Focal therapy for primary and salvage prostate cancer treatment: a narrative review. Transl Androl Urol 2021; 10: 3144–3154.
80. Sjoberg HT, Philippou Y, Magnussen AL, et al. Tumor irradiation combined with vascular-targeted photodynamic therapy enhances antitumor effects in pre-clinical prostate cancer. Br J Cancer 2021; 125: 534–546.
81. Yip W, Sjoberg D, Nogueira L, et al. Final results of a phase i trial of wst11 (tookad soluble) vascular-targeted photodynamic therapy for upper tract urothelial carcinoma. J Urol 2022; 207: e1013.
82. Tsuber V, Kadamov Y, Brautigam L, et al. Mutations in cancer cause gain of cysteine, histidine, and tryptophan at the expense of a net loss of arginine on the proteome level. Biomolecules 2017; 7: 49.
83. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer — a review of current status and future promise. Nature Clin Practice Urology 2009; 6: 18–30.
84. Slesarevskaya MN, Sokolov AV, Kuzmin IV. Photosensitizer in diagnosis and treatment of oncological diseases. Urology Reports (St.-Petersburg) 2013; 3: 10–13.
85. Zaak D, Stroka R, Hoppner M, et al. Photodynamic therapy by means of 5-ALA induced PP1X in human prostate cancer-preliminary results. Med Laser Appl 2003; 18: 91–95.
86. Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008; 102: 556–562.
87. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007; 178: 1974–1979.
88. Cho H-J, Park S-J, Jung WH, et al. Injectable single-component peptide depot: autonomously rechargeable tumor photosensitization for repeated photodynamic therapy. ACS Nano 2020; 14: 15793–15805.
89. Al Saffar H, Chen DC, Delgado C, et al. The current landscape of prostate-specific membrane antigen (PSMA) imaging biomarkers for aggressive prostate cancer. Cancers (Basel) 2024; 16: 39.
90. Wang X, Sun R, Wang J, et al. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer. Theranostics 2022; 12: 2335–2350.
91. Shirke AA, Walker E, Chavali S, et al. A synergistic strategy combining chemotherapy and photodynamic therapy to eradicate prostate cancer. Int J Mol Sci 2024; 25: 7086.
Cite
Cite
Cite
OR
Download to reference manager
If you have citation software installed, you can download citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: March 25, 2026
Keywords
Authors
Metrics and citations
Metrics
Publication usage*
Total views and downloads: 18
*Publication usage tracking started in December 2016
Publications citing this one
Receive email alerts when this publication is cited
Web of Science: 0
Crossref:
There are no citing articles to show.
Figures and tables
Figures & Media
Tables
View Options
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
I am signed in as:
View my profileSign out
I can access personal subscriptions, purchases, paired institutional access and free tools such as favourite journals, email alerts and saved searches.
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
